Product
ATG-017
1 clinical trial
2 indications
Indication
Solid TumorIndication
Hematological MalignancyClinical trial
A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Patients With Advanced Solid Tumors and Hematological MalignanciesStatus: Recruiting, Estimated PCD: 2024-02-29